Gastroenteritis testing market seen reaching $5.55B by 2030

The gastroenteritis testing market is projected to grow from $4.44 billion in 2026 to $5.55 billion by 2030, driven by demand for faster diagnostics, molecular testing and point-of-care services. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Gastroenteritis testing helps identify the pathogen behind stomach and intestinal infections, which can guide faster treatment and better infection control. - Rising bacterial infections and antibiotic resistance are increasing the need for precise diagnostics. - The market’s growth reflects broader demand for faster, more accurate testing in hospitals, clinics and public health settings.

What happened: - The gastroenteritis testing market is expected to rise from $4.18 billion in 2025 to $4.44 billion in 2026. - The market is forecast to reach $5.55 billion by 2030. - The implied CAGR is 6.1% from 2025 to 2026 and 5.8% from 2026 to 2030. - The Business Research Company released the market outlook on Aug. 7, 2026. - The report includes a free sample and the full market report.

The details: - The recent expansion has been supported by reliance on immunoassay and culture-based testing, limited access to advanced molecular diagnostics, higher rates of gastrointestinal infections and stronger diagnostic infrastructure in hospitals and clinics. - Growth is also tied to expanding infectious disease research institutions. - Future growth is expected to come from molecular diagnostic innovation, rising demand for rapid point-of-care testing, more investment in infectious disease research, wider use of laboratory information management systems and market expansion in emerging economies. - Expected trends include broader panels covering viral, bacterial and parasitic agents, stronger epidemiological surveillance and more outbreak-control testing. - Gastroenteritis testing covers methods used to identify the cause of gastroenteritis, an inflammation of the stomach and intestines that can lead to diarrhea, vomiting, abdominal cramps and fever. - Accurate testing can help clinicians choose antibiotics, antivirals or supportive care such as hydration and rest. - In 2024, GOV.UK reported a 9.3% increase in bacteraemia cases caused by antibiotic-resistant bacteria, from 18,740 in 2023 to 20,484 in 2024.

Between the lines: - The shift toward molecular and point-of-care testing suggests laboratories are under pressure to deliver results faster and with more precision. - The report points to a market that is moving from basic infection detection toward broader surveillance and outbreak response. - Antibiotic resistance is turning gastroenteritis testing into more than a clinical tool; it is also becoming part of public health containment.

What's next: - North America remained the largest market in 2025 because of advanced healthcare infrastructure and strong diagnostic capacity. - Asia-Pacific is expected to be the fastest-growing region over the next several years. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company says its 2026 reports include deeper market intelligence, TAM analysis, company scoring matrices, forecasting dashboards and updated graphics and tables. - Contact details for further information were listed for Saumya Sahay at marketing@tbrc.info and by phone in the Americas, Asia and Europe.

The bottom line: - Gastroenteritis testing is a steady-growth diagnostics market with clear momentum from faster technology, rising infection rates and growing demand for outbreak-ready testing.